Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| SQZ Biotechnologies Co | 39,875 | reported | 14 Jun 2023 | tx 29+3,130,970−2,660,136 |
| IRONWOOD PHARMACEUTICALS INC | 38,242 | reported | 01 Apr 2019 | tx 8+42,298−4,056 |
| ALNYLAM PHARMACEUTICALS, INC. | 24,049 | reported | 20 May 2026 | tx 31+163,757−82,836 |
| FRACTYL HEALTH, INC. | 22,500 | reported | 11 Jun 2025 | tx 3+76,050 |
| Hudson Executive Investment Corp. II | 20,000 | reported | 13 Apr 2021 | tx 1+20,000 |
| BIND Therapeutics, Inc | 15,000 | reported | 09 Jun 2015 | tx 2+40,000 |
| Cyclerion Therapeutics, Inc. | 10,000 | reported | 16 Jun 2020 | tx 6+653,625 |
| X4 Pharmaceuticals, Inc | 10,000 | reported | 05 Jun 2018 | tx 3+42,324 |
| PFIZER INC | 5,075 | reported | 31 Dec 2013 | tx 84+2,014,787−367,190 |
| Zoetis Inc. | 5,000 | reported | 06 Feb 2013 | tx 1+5,000 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 20 May 2026 | GRANT_AWARD | ALNYLAM PHARMACEUTICALS, INC. | 838 | 0.00 USD | |
| 20 May 2026 | GRANT_AWARD | ALNYLAM PHARMACEUTICALS, INC. | 1,802 | 0.00 USD | deriv |
| 13 May 2026 | GRANT_AWARD | Elevance Health, Inc. | 563 | 0.00 USD | |
| 13 May 2026 | EXERCISE | ALNYLAM PHARMACEUTICALS, INC. | 11,250 | 70.20 USD | |
| 13 May 2026 | EXERCISE | ALNYLAM PHARMACEUTICALS, INC. | 11,250 | 0.00 USD | deriv |
| 12 Mar 2026 | SALE | Elevance Health, Inc. | 26 | 287.50 USD | |
| 02 Feb 2026 | GRANT_AWARD | Elevance Health, Inc. | 218 | 0.00 USD | |
| 11 Jun 2025 | GRANT_AWARD | FRACTYL HEALTH, INC. | 22,500 | 0.00 USD | deriv |
| 08 May 2025 | GRANT_AWARD | ALNYLAM PHARMACEUTICALS, INC. | 775 | 0.00 USD | |
| 08 May 2025 | GRANT_AWARD | ALNYLAM PHARMACEUTICALS, INC. | 1,558 | 0.00 USD | deriv |
| 13 Mar 2025 | PURCHASE | FRACTYL HEALTH, INC. | 8,550 | 1.17 USD | first after silence |
| 13 Mar 2025 | EXERCISE | ALNYLAM PHARMACEUTICALS, INC. | 2,750 | 131.21 USD | |
| 13 Mar 2025 | EXERCISE | ALNYLAM PHARMACEUTICALS, INC. | 2,750 | 0.00 USD | deriv |
| 25 Jun 2024 | SALE | ALNYLAM PHARMACEUTICALS, INC. | 8,500 | 240.00 USD | |
| 25 Jun 2024 | EXERCISE | ALNYLAM PHARMACEUTICALS, INC. | 8,500 | 131.21 USD | |
| 25 Jun 2024 | EXERCISE | ALNYLAM PHARMACEUTICALS, INC. | 8,500 | 0.00 USD | deriv |
| 29 May 2024 | EXERCISE | ALNYLAM PHARMACEUTICALS, INC. | 30,000 | 66.83 USD | |
| 29 May 2024 | SALE | ALNYLAM PHARMACEUTICALS, INC. | 63 | 149.76 USD | |
| 29 May 2024 | SALE | ALNYLAM PHARMACEUTICALS, INC. | 11,516 | 148.93 USD | |
| 29 May 2024 | SALE | ALNYLAM PHARMACEUTICALS, INC. | 10,121 | 148.21 USD | |
| 29 May 2024 | EXERCISE | ALNYLAM PHARMACEUTICALS, INC. | 30,000 | 0.00 USD | deriv |
| 16 May 2024 | GRANT_AWARD | ALNYLAM PHARMACEUTICALS, INC. | 5,228 | 0.00 USD | deriv |
| 01 Feb 2024 | GRANT_AWARD | FRACTYL HEALTH, INC. | 45,000 | 0.00 USD | deriv |
| 14 Jun 2023 | GRANT_AWARD | SQZ Biotechnologies Co | 39,875 | 0.00 USD | deriv |
| 18 May 2023 | GRANT_AWARD | ALNYLAM PHARMACEUTICALS, INC. | 3,454 | 0.00 USD | deriv |
3 purchases reported after at least 12 months of silence — most recent on 13 Mar 2025.